PARIS--(BUSINESS WIRE)--Genethon, a pioneering gene therapy research organization created by AFM-Telethon, today presented positive results from the Phase 1/2 dose escalation part of an international ...
Based on positive safety and efficacy data in the Phase 1/2 dose escalation phase of the all-in-one study, Genethon expects to launch pivotal trial in Europe in 2025 and in the US. The results showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback